Venetoclax (ABT-199) is an FDA-approved medication that targets Bcl-2 [21]; it is the first-in-class Bcl-2 inhibitor that treats lymphoid cancers [22] and has shown remarkable clinical activity against certain types of haematological malignancies such as chronic lymphocytic leukaemia [23]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.